Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK
β Scribed by Mike Aristides; Michael Lees; Nick Botwood; Jan McKendrick; DeborahA Stephenson; Nikos Maniadakis
- Book ID
- 106294777
- Publisher
- Springer
- Year
- 2003
- Tongue
- French
- Weight
- 219 KB
- Volume
- 4
- Category
- Article
- ISSN
- 1618-7598
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Gemcitabine has modest antitumor activity in advanced pancreatic cancer. New agents are clearly needed. Pemetrexed (ALIMTA) is a novel antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has shown in vitro activity agai
## Abstract MAbβPAM4 is an antiβMUC1 antibody that has been shown to be reactive with 85% of pancreatic adenocarcinomas with no reactivity with normal pancreas or other tissues. Initial clinical studies have shown excellent targeting with high tumor/nontumor ratios. Gemcitabine, an analog of deoxyc
The use of chemotherapy with concurrent radiation therapy remains a standard treatment option for patients with unresectable or resected adenocarcinoma of the pancreas. This treatment strategy is based in large part on data from serial Gastrointestinal Tumor Study Group trials that have included 5-f